18.37

1.59% -0.3392

Arrowhead Pharmaceuticals Inc (ARWR)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ARWR? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$18.71

Offen:

$18.75

24-Stunden-Volumen:

84,402

Relative Volume:

0.08

Marktkapitalisierung:

$2.32B

Einnahmen:

$181.74M

Nettoeinkommen (Verlust:

$-296.81M

KGV:

-10.74

EPS:

-1.71

Netto-Cashflow:

$-402.70M

1W Leistung:

-14.00%

1M Leistung:

-10.14%

6M Leistung:

-26.41%

1J Leistung:

-35.10%

1-Tages-Spanne:

$18.21

$18.79

1-Wochen-Bereich:

$18.03

$21.25

52-Wochen-Spanne:

$17.05

$39.83

Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile

Firmenname

Arrowhead Pharmaceuticals Inc

Sektor

Healthcare (1195)

Branche

Biotechnology (683)

Telefon

626-696-4702

Adresse

177 E COLORADO BLVD, PASADENA, CA

Mitarbeiter

525

Twitter

@ArrowheadPharma

Nächster Verdiensttermin

2024-11-27

Neueste SEC-Einreichungen

ARWR's Discussions on Twitter

Vergleichen Sie ARWR mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ARWR	18.37	2.32B	181.74M	-296.81M	-402.70M	-1.71
VRTX	447.05	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	741.71	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	589.15	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.84	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.92	24.49B	3.30B	-501.07M	1.03B	11.54

Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-12-04	Eingeleitet	BofA Securities	Buy
2023-09-19	Eingeleitet	Citigroup	Neutral
2023-07-21	Eingeleitet	TD Cowen	Outperform
2023-05-12	Herabstufung	SVB Securities	Outperform → Market Perform
2023-04-26	Eingeleitet	SMBC Nikko	Outperform
2023-04-12	Hochstufung	SVB Securities	Market Perform → Outperform
2023-03-21	Eingeleitet	Bernstein	Mkt Perform
2022-09-09	Eingeleitet	Morgan Stanley	Equal-Weight
2022-05-11	Hochstufung	Robert W. Baird	Neutral → Outperform
2022-01-19	Fortgesetzt	Goldman	Buy
2021-08-06	Bestätigt	Chardan Capital Markets	Buy
2021-06-04	Fortgesetzt	Robert W. Baird	Neutral
2021-02-05	Bestätigt	H.C. Wainwright	Buy
2020-12-21	Herabstufung	Robert W. Baird	Outperform → Neutral
2020-12-16	Eingeleitet	UBS	Buy
2020-11-19	Eingeleitet	Citigroup	Buy
2020-05-13	Eingeleitet	RBC Capital Mkts	Outperform
2020-05-08	Hochstufung	Oppenheimer	Perform → Outperform
2020-04-15	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2020-03-24	Hochstufung	SVB Leerink	Underperform → Mkt Perform
2020-03-17	Eingeleitet	Goldman	Neutral
2020-01-21	Eingeleitet	SVB Leerink	Underperform
2019-12-13	Eingeleitet	Oppenheimer	Perform
2019-11-29	Bestätigt	Chardan Capital Markets	Buy
2019-11-27	Bestätigt	B. Riley FBR	Buy
2019-11-25	Hochstufung	Robert W. Baird	Neutral → Outperform
2019-10-24	Herabstufung	Robert W. Baird	Outperform → Neutral
2019-10-22	Bestätigt	Chardan Capital Markets	Buy
2019-10-03	Eingeleitet	Robert W. Baird	Outperform
2018-09-07	Hochstufung	B. Riley FBR	Neutral → Buy
2018-09-06	Bestätigt	Chardan Capital Markets	Buy
2018-08-08	Bestätigt	Cantor Fitzgerald	Overweight
2018-07-02	Bestätigt	Chardan Capital Markets	Buy

Alle ansehen

Arrowhead Pharmaceuticals Inc Aktie (ARWR) Neueste Nachrichten

03:11 AM

Principal Financial Group Inc. Has $5.64 Million Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

03:11 AM

Nov 19, 2024

Familial Chylomicronemia Syndrome Market Expected to Experience Major Growth by 2034, According to DelveInsight | Ionis Pharma, Novartis, Akcea Therapeutics, Arrowhead Pharma, Visirna Therapeutics - Barchart

Nov 19, 2024

Familial Chylomicronemia Syndrome Market Expected - openPR

Nov 19, 2024

Arrowhead Pharmaceuticals (ARWR) to Release Quarterly Earnings on Tuesday - MarketBeat

Nov 19, 2024

Nov 18, 2024

Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran - BioSpace

Nov 18, 2024

Arrowhead seeks FDA nod for rare disease drug - Investing.com

Nov 18, 2024

Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome - Business Wire

Nov 18, 2024

Nov 15, 2024

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Down 6.3%Here's What Happened - MarketBeat

Nov 15, 2024

Nov 10, 2024

When (ARWR) Moves Investors should Listen - Stock Traders Daily

Nov 10, 2024

Privium Fund Management B.V. Has $6.46 Million Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Nov 10, 2024

Nov 08, 2024

Leerink Partnrs Has Positive Outlook of ARWR FY2024 Earnings - MarketBeat

Nov 08, 2024

Nov 06, 2024

Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results - BioSpace

Nov 06, 2024

Nov 04, 2024

Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences - BioSpace

Nov 04, 2024

Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome - BioSpace

Nov 04, 2024

Nov 03, 2024

abrdn plc Has $7.77 Million Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Nov 03, 2024

Nov 01, 2024

Arrowhead Launches FCS Awareness Campaign - Baystreet.ca

Nov 01, 2024

Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, 'We'll Get There Soon,' to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome - Quantisnow

Nov 01, 2024

Arrowhead Pharmaceuticals Launches New Disease Awareness Campaig - GuruFocus.com

Nov 01, 2024

In the wake of Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest US$108m market cap drop, institutional owners may be forced to take severe actions - Simply Wall St

Nov 01, 2024

Oct 31, 2024

International Assets Investment Management LLC Takes Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Oct 31, 2024

Oct 30, 2024

(ARWR) Long Term Investment Analysis - Stock Traders Daily

Oct 30, 2024

Assenagon Asset Management S.A. Has $5.68 Million Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Oct 30, 2024

Oct 28, 2024

Analysts Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Target Price at $45.33 - MarketBeat

Oct 28, 2024

Oct 21, 2024

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Down 6.4%Here's Why - MarketBeat

Oct 21, 2024

Oct 20, 2024

(ARWR) Trading Signals - Stock Traders Daily

Oct 20, 2024

Oct 18, 2024

Buffington Mohr McNeal Takes Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Oct 18, 2024

Oct 17, 2024

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded at StockNews.com - MarketBeat

Oct 17, 2024

Oct 16, 2024

State Street Corp's Strategic Acquisition in Arrowhead Pharmaceu - GuruFocus.com

Oct 16, 2024

80+ Pharma Companies Unite to Shape the Future of RNA-Based Therapeutics | DelveInsight - GlobeNewswire

Oct 16, 2024

Oct 15, 2024

Alpha-1 Antitrypsin Deficiency Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, MOA, ROA by DelveInsight | Apic Bio, Dicerna Pharma, Peak Bio, Arrowhead Pharma - The Globe and Mail

Oct 15, 2024

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)October 14, 2024 - BioSpace

Oct 15, 2024

Oct 11, 2024

HC Wainwright Reiterates Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - MarketBeat

Oct 11, 2024

Arrowhead Pharmaceuticals (STU:HDP1) EV-to-Revenue : 93.89 (As of Oct. 11, 2024) - GuruFocus.com

Oct 11, 2024

Oct 10, 2024

Dimensional Fund Advisors LP Boosts Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Oct 10, 2024

Oct 09, 2024